Webcast Alert: Isis Pharmaceuticals Reviews Data Including ISIS 301012 and ISIS 113715 Results and Highlights Presented at the American Diabetes Association's (ADA) 65th Scientific Sessions

CARLSBAD, Calif., June 9, 2005 /PRNewswire-FirstCall via COMTEX/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast: What: Isis Pharmaceuticals Reviews Data Presented at ADA Including ISIS 301012 and ISIS 113715 Results and Highlights When: Tuesday, June 14, 2005, at 4:00 p.m. (ET) / 1:00 p.m. (PT) Where: www.isispharm.com How: Live on the Internet. Simply log onto our website listed above. Contact: Claudine Prowse, Ph.D. Investor Relations and Corporate Communications (760) 603-2331 If you are unable to participate during the live event, a replay of the webcast will be available at www.isispharm.com. Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 11 antisense drugs in development to treat metabolic, cardiovascular and inflammatory diseases, and cancer. In its Ibis division, Isis is developing and commercializing the TIGER biosensor system, a system that has the potential to revolutionize the identification of infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of more than 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com. SOURCE Isis Pharmaceuticals Claudine Prowse, Ph.D., Investor Relations and Corporate Communications of Isis Pharmaceuticals, +1-760-603-2331 http://www.prnewswire.com

The release as fetched from its publisher. ionis.com ↗